Profile data is unavailable for this security.
About the company
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
- Revenue in USD (TTM)477.00k
- Net income in USD-11.57m
- Incorporated1994
- Employees16.00
- LocationBioCardia Inc320 Soquel WaySUNNYVALE 94085United StatesUSA
- Phone+1 (650) 226-0123
- Fax+1 (650) 631-3731
- Websitehttps://www.biocardia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endexx Corp | 4.64m | 6.93m | 9.57m | -- | 1.42 | -- | 1.61 | 2.06 | 0.0133 | 0.0133 | 0.0091 | -0.0255 | 0.6773 | 4.37 | 13.54 | -- | 86.51 | -- | -- | -- | 28.73 | -- | 127.74 | -- | 0.0664 | -- | -- | -- | 228.66 | -- | 28.26 | -- | -- | -- |
| Eterna Therapeutics Inc | 68.00k | -21.68m | 9.58m | 8.00 | -- | 4.29 | -- | 140.83 | -4.08 | -4.08 | 0.0128 | 0.4128 | 0.0019 | -- | 0.0988 | 8,500.00 | -60.69 | -169.05 | -75.78 | -223.00 | -173.53 | -- | -31,864.71 | -682.61 | -- | -33.19 | 0.7813 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| BioRestorative Therapies Inc | 145.80k | -14.42m | 9.61m | 11.00 | -- | 0.5795 | -- | 65.93 | -3.54 | -3.54 | 0.0346 | 2.45 | 0.01 | -- | 8.26 | 13,254.55 | -99.26 | -199.86 | -104.68 | -334.04 | -- | -- | -9,887.16 | -19,887.03 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 22.06 | -- | 67.77 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -24.22m | 9.94m | 20.00 | -- | 0.0293 | -- | -- | -42.37 | -42.37 | 0.00 | 23.93 | 0.00 | -- | -- | 0.00 | -74.28 | -- | -90.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -59.08m | 10.13m | 7.00 | -- | -- | -- | -- | -1.42 | -1.42 | 0.00 | -2.41 | 0.00 | -- | -- | 0.00 | -168.38 | -83.69 | -227.94 | -97.54 | -- | -- | -- | -- | -- | -4.78 | 7.60 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Guardion Health Sciences Inc | 12.25m | 158.03k | 10.14m | 9.00 | 63.58 | 1.24 | 57.17 | 0.8283 | 0.1243 | 0.1243 | 9.66 | 6.39 | 0.729 | 2.36 | 5.83 | 1,360,951.00 | 0.9405 | -77.90 | 1.12 | -86.55 | 44.04 | 42.45 | 1.29 | -176.93 | 6.98 | -- | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| BioCardia Inc | 477.00k | -11.57m | 10.40m | 16.00 | -- | -- | -- | 21.80 | -0.5525 | -0.5525 | 0.0225 | -0.0677 | 0.0747 | -- | 3.61 | 29,812.50 | -181.08 | -107.34 | -414.21 | -154.17 | -- | -- | -2,425.79 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| National Graphite Corp | 0.00 | -1.97m | 10.49m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Chromocell Therapeutics Corp | 0.00 | -7.38m | 10.52m | 4.00 | -- | -- | -- | -- | -1.28 | -1.28 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -9,746.19 | -- | -- | -- | -- | -- | -- | -- | -- | -13.23 | -- | -- | -- | -- | -200.20 | -- | -- | -- |
| Mystic Holdings Inc | -100.00bn | -100.00bn | 10.55m | 79.00 | -- | 0.4223 | -- | -- | -- | -- | -- | 0.2155 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2228 | -- | 0.1849 | -- | 199.82 | -- | 34.32 | -- | -- | -- |
| eFFECTOR Therapeutics Inc | 0.00 | -35.81m | 10.58m | 14.00 | -- | -- | -- | -- | -17.11 | -17.11 | 0.00 | -1.94 | 0.00 | -- | -- | 0.00 | -144.34 | -- | -- | -- | -- | -- | -- | -- | -- | -17.38 | 1.43 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
| Organovo Holdings Inc | 242.00k | -19.09m | 10.74m | 15.00 | -- | 1.70 | -- | 44.39 | -2.17 | -2.17 | 0.0275 | 0.6283 | 0.0143 | -- | 4.44 | 12,100.00 | -112.40 | -51.24 | -123.59 | -54.90 | -- | -- | -7,886.36 | -1,269.78 | -- | -- | 0.00 | -- | -75.33 | -39.60 | -50.76 | -- | 5.99 | -- |
| Molecular Templates Inc | 57.31m | -8.12m | 10.93m | 62.00 | -- | 2.12 | -- | 0.1907 | -1.55 | -1.55 | 12.74 | 0.7837 | 0.8622 | -- | -- | 924,290.30 | -12.22 | -51.78 | -27.76 | -73.14 | -- | -- | -14.18 | -228.33 | -- | -7.24 | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| BioNexus Gene Lab Corp | 9.77m | -2.63m | 10.95m | 30.00 | -- | 1.13 | -- | 1.12 | -0.1389 | -0.1389 | 0.6873 | 0.5466 | 0.9703 | 7.98 | 5.33 | -- | -26.11 | -3.83 | -31.86 | -5.02 | 13.61 | 14.55 | -26.91 | -3.04 | 4.24 | -186.19 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Moleculin Biotech Inc | 0.00 | -29.77m | 11.18m | 18.00 | -- | 0.4289 | -- | -- | -15.06 | -15.06 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -62.25 | -46.84 | -70.87 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
Data as of May 01 2024. Currency figures normalised to BioCardia Inc's reporting currency: US Dollar USD
7.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| CM Management LLCas of 31 Dec 2023 | 700.00k | 2.70% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 646.74k | 2.50% |
| Geode Capital Management LLCas of 31 Dec 2023 | 159.65k | 0.62% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 88.30k | 0.34% |
| Family Management Corp.as of 31 Dec 2023 | 77.50k | 0.30% |
| G1 Execution Services LLCas of 31 Dec 2023 | 65.43k | 0.25% |
| Virtu Americas LLCas of 31 Dec 2023 | 41.35k | 0.16% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 40.34k | 0.16% |
| Citadel Securities LLCas of 31 Dec 2023 | 33.63k | 0.13% |
| Brown Advisory LLCas of 31 Mar 2024 | 33.09k | 0.13% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
